Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Net Cash Flow (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Net Cash Flow for 6 consecutive years, with -$39.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Cash Flow fell 1716.49% to -$39.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $37.4 million, a 367.83% increase, with the full-year FY2024 number at $47.3 million, up 2294.25% from a year prior.
  • Net Cash Flow was -$39.5 million for Q3 2025 at Inhibikase Therapeutics, down from $4.3 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $55.6 million in Q4 2024 to a low of -$39.5 million in Q3 2025.
  • A 5-year average of $1.3 million and a median of -$2.2 million in 2024 define the central range for Net Cash Flow.
  • Biggest YoY gain for Net Cash Flow was 694632.18% in 2021; the steepest drop was 81674.89% in 2021.
  • Inhibikase Therapeutics' Net Cash Flow stood at -$4.1 million in 2021, then surged by 134.34% to $1.4 million in 2022, then plummeted by 504.95% to -$5.7 million in 2023, then soared by 1075.7% to $55.6 million in 2024, then plummeted by 171.02% to -$39.5 million in 2025.
  • Per Business Quant, the three most recent readings for IKT's Net Cash Flow are -$39.5 million (Q3 2025), $4.3 million (Q2 2025), and $17.0 million (Q1 2025).